Adynxx, Inc.

LANGHORNE, PA How do I update this listing?

Adynxx is based out of Langhorne. HepaLife Technologies, Inc. is a development stage biotechnology company focused on the identification, development and eventual commercialization of technologies and products for liver toxicity detection and the treatment of various forms of liver dysfunction and disease. The Company is also concentrating its efforts on creating the first-of-its-kind artificial liver device and developing proprietary in-vitro toxicology and pre-clinical drug testing platforms.Whalewisdom has at least 123 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2017-03-13. The notice included securities offered of Equity

Create Alert

Contact Info

adynxx, inc.
2150 CABOT BOULEVARD WEST
LANGHORNE PA    19047

Business Phone: 215-702-8550
SEC SIC CODE:
3841-SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2017-03-13 D BIOTECHNOLOGY Equity 2,900,000 2,770,000 130,000
2014-05-15 D BIOTECHNOLOGY Equity 7,003,080 2,003,080 5,000,000
2014-04-28 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 14,975,000 14,975,000 0
2013-11-25 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 6,000,000 6,000,000 0
2013-11-25 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 7,000,000 7,000,000 0
2013-11-25 D BIOTECHNOLOGY Equity 651,578 651,578 0
2013-11-18 D/A BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 1,000,000 1,000,000 0
2013-11-06 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 1,000,000 1,000,000 0
2013-07-09 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 2,000,000 1,976,925 23,075
2013-06-10 D/A BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 3,000,000 1,100,000 1,900,000
2013-05-07 D/A BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 3,000,000 812,000 2,188,000
2013-04-24 D/A BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 3,000,000 702,000 2,298,000
2013-04-18 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 3,000,000 236,000 2,764,000
2012-11-15 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 815,000 815,000 0
2012-08-29 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 295,000 265,000 30,000
2012-03-01 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 1,050,000 1,050,000 0
2011-03-17 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 1,000,000 1,000,000 0
2010-05-25 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 2,500,000 1,425,000 1,075,000
2010-05-25 D BIOTECHNOLOGY Equity 10,600,000 10,600,000 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
BRAD BARTON subscription required
    EXECUTIVE OFFICER
BRIAN POSNER subscription required
    EXECUTIVE OFFICER
DAVID JOHNSON subscription required
    EXECUTIVE OFFICER DIRECTOR
DAVID STEFANSKY subscription required
    EXECUTIVE OFFICER DIRECTOR
GARY RESTANI subscription required
    DIRECTOR
JAMES SAPIRSTEIN subscription required
    EXECUTIVE OFFICER DIRECTOR
JEFFREY SKLAR subscription required
    DIRECTOR
JEROME ZELDIS subscription required
    DIRECTOR
JOSEPH M. LEONE subscription required
    DIRECTOR
JOSEPH SIERCHIO subscription required
    DIRECTOR
KENNETH LONDONER subscription required
    DIRECTOR
KENNETH PEARSEN subscription required
    DIRECTOR
MARK WAGNER subscription required
    DIRECTOR
MICHAEL GOLDBERG subscription required
    DIRECTOR
NOCHUM STEIN subscription required
    DIRECTOR
PELLEGRINO PIONATI subscription required
    EXECUTIVE OFFICER
PERRY KARSEN subscription required
    DIRECTOR
RICHARD ROSENBLUM subscription required
    EXECUTIVE OFFICER
STEVEN C. BERGER subscription required
    EXECUTIVE OFFICER
WINSTON KUNG subscription required
    DIRECTOR

Elevate your investments